<SEC-DOCUMENT>0001140361-25-028453.txt : 20250801
<SEC-HEADER>0001140361-25-028453.hdr.sgml : 20250801
<ACCEPTANCE-DATETIME>20250801211233
ACCESSION NUMBER:		0001140361-25-028453
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250730
FILED AS OF DATE:		20250801
DATE AS OF CHANGE:		20250801

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Torti Frank
		CENTRAL INDEX KEY:			0001647805
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		251177783

	MAIL ADDRESS:	
		STREET 1:		2855 SAND HILL ROAD
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7TH FLOOR, 50 BROADWAY
		CITY:			LONDON
		NON US STATE TERRITORY:  	UNITED KINGDOM
		PROVINCE COUNTRY:   	X0
		ZIP:			SW1H 0DB
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7TH FLOOR, 50 BROADWAY
		CITY:			LONDON
		NON US STATE TERRITORY:  	UNITED KINGDOM
		PROVINCE COUNTRY:   	X0
		ZIP:			SW1H 0DB
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-07-30</periodOfReport>

    <issuer>
        <issuerCik>0001635088</issuerCik>
        <issuerName>Roivant Sciences Ltd.</issuerName>
        <issuerTradingSymbol>ROIV</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001647805</rptOwnerCik>
            <rptOwnerName>Torti Frank</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ROIVANT SCIENCES LTD.</rptOwnerStreet1>
            <rptOwnerStreet2>7TH FLOOR, 50 BROADWAY</rptOwnerStreet2>
            <rptOwnerCity>LONDON</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>SW1H 0DB</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>true</isOfficer>
            <officerTitle>President and Vant Chair</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2025-07-30</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1836547</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1836547</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2025-07-30</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>11900000</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13736547</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Reflects an award of restricted stock units with respect to Common Shares (&quot;RSUs&quot;), with a vesting commencement date of March 31, 2025, which service-vest (i) 20% on the first anniversary of the vesting commencement date and (ii) in 16 successive equal quarterly installments thereafter, subject to the reporting person's continuous service through each vesting date.</footnote>
        <footnote id="F2">Reflects an award of performance restricted stock units with respect to Common Shares (&quot;PSUs&quot;) across six share price hurdle tranches, as follows: $15.00 (14.71% of PSUs); $17.50 (7.35% of PSUs); $20.00 (8.82% of PSUs); $22.50 (11.77% of PSUs); $25.00 (22.06% of PSUs); and $30.00 (35.29% of PSUs). The PSUs will vest tranche-by-tranche on the first date that both the performance condition and the service condition with respect to the applicable tranche of the PSUs has been satisfied. The performance condition will be deemed satisfied for each tranche of PSUs on the first date, during the performance period ending on July 26, 2029, when the Company's trailing 30-day volume weighted average trading price per share for trading days during the performance period exceeds the share price hurdle applicable to such tranche (as specified above). (Continued in footnote 3)</footnote>
        <footnote id="F3">(Continued from footnote 2) The service condition will be deemed satisfied for each tranche of PSUs on the first anniversary of the date on which the performance condition is first satisfied with respect to such tranche, subject to the reporting person's continuous service through such anniversary. In addition, following the satisfaction of the performance condition and service condition and the vesting of any tranche of the PSUs, the common shares underlying the applicable vested tranche of PSUs are subject to a further two-year holding period before such common shares may be sold.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>By: /s/ Jo Chen, as Attorney-in-Fact for Frank Torti</signatureName>
        <signatureDate>2025-08-01</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
